Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beam Therapeutics Inc
(NQ:
BEAM
)
22.88
-0.25 (-1.10%)
Streaming Delayed Price
Updated: 2:40 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection
September 19, 2022
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 07, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Apple, Amazon, HP And Other Big Losers From Friday
August 29, 2022
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Recap: Beam Therapeutics Q2 Earnings
August 09, 2022
Beam Therapeutics (NASDAQ:BEAM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses
August 01, 2022
The company didn't identify the reason behind the clinical hold in cancer treatment.
Via
Investor's Business Daily
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
August 29, 2022
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Via
Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
August 25, 2022
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.
Via
Benzinga
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
August 22, 2022
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.
Via
InvestorPlace
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
August 17, 2022
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.
Via
InvestorPlace
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
August 17, 2022
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 04, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
August 03, 2022
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.
Via
InvestorPlace
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 01, 2022
Via
Benzinga
Why Is Target (TGT) Stock in the Spotlight Today?
August 01, 2022
Target (TGT) stock is in the news today as investors react to a new note from Jefferies that gives the retail company flak.
Via
InvestorPlace
Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News
August 01, 2022
Beam Therapeutics (BEAM) stock is slipping on Monday after the U.S. Food and Drug Administration placed a clinical hold on one of its drugs.
Via
InvestorPlace
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 01, 2022
Via
Benzinga
Beam Therapeutics Shares Decline Following FDA's Clinical Hold On Leukemia Study
August 01, 2022
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Beam Therapeutics’ (NASDAQ: BEAM) Investigational New Drug (IND) application for the candidate BEAM-201 in the treatment of...
Via
Benzinga
Will a Recession Cause a Housing Crash in 2022?
July 27, 2022
For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 26, 2022
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 20, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
July 20, 2022
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Via
Benzinga
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage
July 18, 2022
Via
Benzinga
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol
July 12, 2022
This could offer an improvement over CRISPR, which requires cutting DNA.
Via
Investor's Business Daily
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.
Via
InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics
July 07, 2022
Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ:
Via
Benzinga
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
July 05, 2022
The FDA's advisors recently backed Pfizer's Covid shot for young children.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.